Treatment groups of the EORTC/GELA and GHSG.
| . | EORTC . | GHSG . |
|---|---|---|
| Abbreviations: GHSG, German Hodgkin Lymphoma Study Group; EORTC, European Organization for Research and Treatment of Cancer; NLPHD, nodular lymphocyte predominant Hodgkin’s disease; RF, risk factor | ||
| † erythrocyte sedimentation rate (≥ 50 without or ≥ 30 with B symptoms) | ||
| Risk factors (RF) | A. large mediastinal mass | A. large mediastinal mass |
| B. age ≥50 years | B. extranodal disease | |
| C. elevated ESR* | C. elevated ESR† | |
| D. ≥ 4 involved regions | D. ≥ 3 involved regions | |
| Treatment Groups | ||
| Lymphocyte predominance | NLPHD histology in supradiaphragmatic CS I–II, no RFs | nLPHD histology in CS I–II with no RFs |
| Early Stage Favorable | CS I–II supradiaphragmatic with no RF | CS I–II with no RF |
| Early Stage Unfavorable (intermediate) | CS I–II supradiaphragmatic with one or more RF | CS I, CSIIA with one or more RF; CS IIB with C/D but without A/B |
| Advanced Stage | CS III–IV | CS IIB with A/B; CS III–IV |
| . | EORTC . | GHSG . |
|---|---|---|
| Abbreviations: GHSG, German Hodgkin Lymphoma Study Group; EORTC, European Organization for Research and Treatment of Cancer; NLPHD, nodular lymphocyte predominant Hodgkin’s disease; RF, risk factor | ||
| † erythrocyte sedimentation rate (≥ 50 without or ≥ 30 with B symptoms) | ||
| Risk factors (RF) | A. large mediastinal mass | A. large mediastinal mass |
| B. age ≥50 years | B. extranodal disease | |
| C. elevated ESR* | C. elevated ESR† | |
| D. ≥ 4 involved regions | D. ≥ 3 involved regions | |
| Treatment Groups | ||
| Lymphocyte predominance | NLPHD histology in supradiaphragmatic CS I–II, no RFs | nLPHD histology in CS I–II with no RFs |
| Early Stage Favorable | CS I–II supradiaphragmatic with no RF | CS I–II with no RF |
| Early Stage Unfavorable (intermediate) | CS I–II supradiaphragmatic with one or more RF | CS I, CSIIA with one or more RF; CS IIB with C/D but without A/B |
| Advanced Stage | CS III–IV | CS IIB with A/B; CS III–IV |